Metformin, a commonly prescribed medication for type 2 diabetes, was found to reduce knee pain in overweight or obese patients with osteoarthritis. A randomized clinical trial reported a reduction in knee pain in the metformin group compared to placebo, though the clinical significance was inconclusive. The drug demonstrated a good safety profile, with gastrointestinal adverse effects being the most commonly reported. The study suggested that metformin's anti-inflammatory and metabolic actions could be beneficial in addressing the therapeutic gap in osteoarthritis treatment for obese patients.

Source: JAMA